COPD – Page 3 – Medxy AI

Targeting IL-33 in COPD: Insights from the Phase 2a FRONTIER-4 Trial of Tozorakimab

By MedXY 09/19/2025

The FRONTIER-4 phase 2a trial evaluated tozorakimab, an anti-IL-33 monoclonal antibody, in moderate-to-severe COPD with chronic bronchitis. While the primary endpoint was unmet in the overall population, efficacy signals emerged in patients with frequent exacerbations, supporting ongoing phase 3 studies.

news Respiratory Specialties

Decoding Thoracoabdominal Asynchrony in Severe COPD: Insights Into Exercise Limitation and Respiratory Support

By MedXY 09/19/2025

This study reveals how thoracoabdominal asynchrony (TAA) during exercise reflects lung function severity and predicts breathlessness in very severe COPD patients, highlighting its potential to guide personalized respiratory support strategies during rehabilitation.

news Respiratory Specialties

Evaluating Carbocysteine in Mild-to-Moderate COPD: Insights From a Large Multicenter Controlled Trial

By MedXY 09/10/2025

A large phase 4 trial found carbocysteine did not significantly reduce exacerbation rates or improve lung function in mild-to-moderate COPD, suggesting limited benefit beyond severe cases.

Clinical Updates news Respiratory Specialties

Nasal High Flow Therapy During Exercise in COPD: Incremental Gains in Dyspnoea and Endurance

By MedXY 08/08/2025

Nasal high flow therapy modestly improves tidal volume and dyspnoea during exercise in severe COPD but has minimal effect on respiratory muscle workload or endurance capacity.

Clinical Updates news

Vitamin D Deficiency and Accelerated Bone Loss in Mild to Moderate COPD: New Insights from the Multi-Ethnic Study of Atherosclerosis

By MedXY 08/06/2025

Mild to moderate COPD accelerates vertebral bone mineral density loss only in individuals with vitamin D deficiency, highlighting a modifiable risk factor for osteoporosis in this population.

Clinical Updates news Respiratory Specialties

AI-Enhanced Spirometry Interpretation in Primary Care: Evidence from a Randomized Controlled Trial

By MedXY 08/05/2025

AI decision support significantly improves primary care clinicians’ accuracy in spirometry diagnosis, especially for COPD, addressing a key gap in respiratory disease management.

Clinical Updates news Respiratory Specialties

Young COPD: Prevalence and Prognostic Impact in Adults Under 50 Years

By MedXY 08/05/2025

COPD in adults under 50 affects 4.5% of this population and is linked to increased risks of early mortality and serious cardiopulmonary events, underscoring the need for early identification and intervention.

Clinical Updates Respiratory Specialties

Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial

By MedXY 08/02/2025

Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.